The global radiodermatitis market size is expected to reach USD 557.1 million by 2030. The market is expected to expand at a CAGR of 3.9% from 2023 to 2030. The market is expected to grow at an unprecedented rate owing to the growing prevalence of cancer patients undergoing radiation therapy. The unmet medical needs of patients in both emerging and developed nations are another factor that increases the demand for radiodermatitis treatment. As the prevalence of diabetes and obesity increases, these individuals are more likely to suffer from cancer. This factor is probably going to increase the cases of radiodermatitis and increase the need for radiation therapy. Furthermore, higher consumption of alcohol and smoking are additional cancer risk factors, which will certainly increase demand for radiodermatitis medications.
The COVID-19 pandemic has a significant impact on the radiodermatitis market. Various regions imposed restrictions or lockdowns of varying severity implemented to curb the pandemic, with different outcomes.Globally, many cancer centers have reported substantial decreases in the number of patients diagnosed with and treated for cancer during the pandemic. Hospitals across the globe have decreased radiotherapy treatment as there was a shift to support the COVID-19 pandemic. However, with the ease of the restrictions by the 3rd quarter of 2020, radiotherapy treatment started to increase which resulted in the growth of the radiodermatitis market.
Asia Pacific dominated the overall market in terms of revenue and growth rate during the forecast period. The presence of increasing cancer research activities, advancing healthcare infrastructure, and expenditure are some of the factors responsible for garnering a greater share of the segment. As a result of unmet patient needs, Asia Pacific is also likely to have profitable expansion over the course of the projection period. The market's second-largest share was accounted for by North America. The increasing incidence of radiation burns along with the high demand for skin grafts and substitutes is expected to further drive the growth of this market.
This product will be delivered within 1-3 business days.
The COVID-19 pandemic has a significant impact on the radiodermatitis market. Various regions imposed restrictions or lockdowns of varying severity implemented to curb the pandemic, with different outcomes.Globally, many cancer centers have reported substantial decreases in the number of patients diagnosed with and treated for cancer during the pandemic. Hospitals across the globe have decreased radiotherapy treatment as there was a shift to support the COVID-19 pandemic. However, with the ease of the restrictions by the 3rd quarter of 2020, radiotherapy treatment started to increase which resulted in the growth of the radiodermatitis market.
Asia Pacific dominated the overall market in terms of revenue and growth rate during the forecast period. The presence of increasing cancer research activities, advancing healthcare infrastructure, and expenditure are some of the factors responsible for garnering a greater share of the segment. As a result of unmet patient needs, Asia Pacific is also likely to have profitable expansion over the course of the projection period. The market's second-largest share was accounted for by North America. The increasing incidence of radiation burns along with the high demand for skin grafts and substitutes is expected to further drive the growth of this market.
Radiodermatitis Market Report Highlights
- The topical products segment captured the largest share in the product segment in 2022. The dominant share is attributable to ease in availability, greater convenience, and superiority over oral products. Topical products are also anticipated to grow at an exponential rate owing to their availability in various formulations such as creams, gels, and ointments according to the requirement of the patient
- In 2022, the retail pharmacies segment accounted for a substantial share of the distribution channel segment owing to the rising number of pharmacies. The retail pharmacies may capture large percent of prescriptions written in the hospital
- Due to the high number of cancer patients in this area, Asia Pacific held the highest share of the market
- North America held the second largest share owing to extensive R&D activities that have fueled high-potential growth opportunities. In addition, the availability of therapeutically advanced products across North America is one of the major factors contributing toward its high share
- The competition is marked by major players undertaking strategies such as product launches, distribution agreements, and strategic collaborations that have led to significant growth in their respective market share
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Research Methodology & Scope1.1 Region Wise Market Calculation
1.1.1 Region-wise market: Base estimates
1.1.2 Global market: CAGR calculation
1.2 Region-Based Segment Share Calculation
1.3 List of Secondary Sources
Chapter 2 Executive Summary
Chapter 3 Radiodermatitis Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.3 Market Restraint Analysis
3.4 Penetration & Growth Prospect Mapping
3.5 Radiodermatitis Market - SWOT Analysis, By Factor (Political & legal, economic and technological)
3.6 Industry Analysis - Porter’s
3.7 COVID-19 Impact Analysis
Chapter 4 Radiodermatitis Market: Product Estimates & Trend Analysis
4.1 Radiodermatitis Market: Product Movement Analysis
4.2 Topical
4.2.1 Topical Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.2.2 Corticosteroids
4.2.2.1 Corticosteroids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.2.3 Hydrophilic Creams
4.2.3.1 Hydrophilic Creams Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.2.4 Antibiotics
4.2.4.1 Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.2.5 Others
4.2.5.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3 Oral
4.3.1 Oral Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4 Dressings
4.4.1 Dressings Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.2 Hydrogel & Hydrocolloid Dressing
4.4.2.1 Hydrogel & Hydrocolloid Dressing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.3 No Sting Barrier Film
4.4.3.1 No Sting Barrier Film Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.4 Honey Impregnated Gauze
4.4.4.1 Honey Impregnated Gauze Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.5 Silicone Coated Dressings
4.4.5.1 Silicone Coated Dressings Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.6 Others
4.4.6.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 5 Radiodermatitis Market: Distribution Channel Estimates & Trend Analysis
5.1 Radiodermatitis Market: Distribution Channel Movement Analysis
5.2 Hospital Pharmacies
5.2.1 Hospital Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3 Retail Pharmacies
5.3.1 Retail Pharmacies Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4 Online Pharmacies
5.4.1 Online Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 6 Radiodermatitis Market: Regional Estimates & Trend Analysis, by Product & Distribution Channel
6.1 Radiodermatitis Market Shares By Region, 2022 & 2030
6.2 North America
6.2.1 North America Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.2.2 North America Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.2.3 U.S.
6.2.3.1 U.S. Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.2.3.2 U.S. Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.2.4 Canada
6.2.4.1 Canada Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.2.4.2 Canada Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.3 Europe
6.3.1 Europe Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.3.2 Europe Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.3.3 U.K.
6.3.3.1 U.K. radiodermatitis Market Estimates And Forecasts, 2018 - 2030(USD Million)
6.3.3.2 U.K. Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.3.3.3 U.K. Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.3.4 Germany
6.3.4.1 Germany Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.3.4.2 Germany Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.3.5 France
6.3.5.1 France Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.3.5.2 France Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.3.6 Italy
6.3.6.1 Italy Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.3.6.2 Italy Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.3.7 Spain
6.3.7.1 Spain Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.3.7.2 Spain Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.3.8 Denmark
6.3.8.1 Denmark Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.3.8.2 Denmark Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.3.9 Sweden
6.3.9.1 Sweden Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.3.9.2 Sweden Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.3.10 Norway
6.3.10.1 Norway Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.3.10.2 Norway Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.4.2 Asia Pacific Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.4.3 Japan
6.4.3.1 Japan Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.4.3.2 Japan Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.4.4 China
6.4.4.1 China Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.4.4.2 China Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.4.5 India
6.4.5.1 India Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.4.5.2 India Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.4.6 Australia
6.4.6.1 Australia Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.4.6.2 Australia Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.4.7 South Korea
6.4.7.1 South Korea Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.4.7.2 South Korea Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.4.8 Thailand
6.4.8.1 Thailand Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.4.8.2 Thailand Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.5 Latin America
6.5.1 Latin America Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.5.2 Latin America Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.5.3 Brazil
6.5.3.1 Brazil Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.5.3.2 Brazil Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.5.4 Mexico
6.5.4.1 Mexico Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.5.4.2 Mexico Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.5.5 Argentina
6.5.5.1 Argentina Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.5.5.2 Argentina Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.6 MEA
6.6.1 MEA Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.6.2 MEA Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.6.3 South Africa
6.6.3.1 South Africa Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.6.3.2 South Africa Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.6.4 Saudi Arabia
6.6.4.1 Saudi Arabia Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.6.4.2 Saudi Arabia Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.6.5 UAE
6.6.5.1 UAE Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.6.5.2 UAE Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
6.6.6 Kuwait
6.6.6.1 Kuwait Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
6.6.6.2 Kuwait Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Market Participation Categorization
7.3 Company Profiles
7.3.1 Stratpharma AG
7.3.1.1 Company Overview
7.3.1.2 Financial performance
7.3.1.3 Product benchmarking
7.3.1.4 Strategic initiatives
7.3.2 Smith & Nephew
7.3.2.1 Company Overview
7.3.2.2 Financial Performance
7.3.2.3 Product Benchmarking
7.3.2.4 Strategic initiatives
7.3.3 Molnlycke Health Care AB
7.3.3.1 Company Overview
7.3.3.2 Financial Performance
7.3.3.3 Product Benchmarking
7.3.3.4 Strategic initiatives
7.3.4 Derma Sciences Inc.
7.3.4.1 Company Overview
7.3.4.2 Financial Performance
7.3.4.3 Product Benchmarking
7.3.4.4 Strategic initiatives
7.3.5 ConvaTec Inc.
7.3.5.1 Company Overview
7.3.5.2 Financial performance
7.3.5.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.6 BMG Pharma S.R.L.
7.3.6.1 Company Overview
7.3.6.2 Financial performance
7.3.6.3 Product benchmarking
7.3.6.4 Strategic initiatives
7.3.7 Acelity
7.3.7.1 Company Overview
7.3.7.2 Financial performance
7.3.7.3 Product benchmarking
7.3.7.4 Strategic initiatives
7.3.8 3M
7.3.8.1 Company Overview
7.3.8.2 Financial Performance
7.3.8.3 Product Benchmarking
7.3.9 Alliqua BioMedical
7.3.9.1 Company Overview
7.3.9.2 Financial performance
7.3.9.3 Product benchmarking
7.3.4.4 Strategic initiatives
List of Tables
Table 1 List of secondary sources
TABLE 2 List of Abbreviations
List of Figures
Fig. 1 Market outlook
FIG. 2 Market segmentation & scope
FIG. 3 Market driver relevance analysis (Current & future impact)
FIG. 4 Market restraint relevance analysis (Current & future impact)
FIG. 5 Penetration & growth prospect mapping
FIG. 6 SWOT Analysis, By Factor (Political & legal, economic and technological)
FIG. 7 Porter’s Five Forces Analysis
FIG. 8 Radiodermatitis market, product outlook: Key takeaways
FIG. 9 Radiodermatitis market: Product movement analysis
FIG. 10 Global topical market, 2018 - 2030 (USD Million)
FIG. 11 Global corticosteroid market, 2018 - 2030 (USD Million)
FIG. 12 Global hydrophilic creams market, 2018 - 2030 (USD Million)
FIG. 13 Global antibiotics market, 2018 - 2030 (USD Million)
FIG. 14 Global others market, 2018 - 2030 (USD Million)
FIG. 15 Global oral market, 2018 - 2030 (USD Million)
FIG. 16 Global dressings market, 2018 - 2030 (USD Million)
FIG. 17 Global hydrogel & hydrocolloid dressing market, 2018 - 2030 (USD Million)
FIG. 18 Global no sting barrier film market, 2018 - 2030 (USD Million)
FIG. 19 Global honey impregnated gauze market, 2018 - 2030 (USD Million)
FIG. 20 Global silicone coated dressings market, 2018 - 2030 (USD Million)
FIG. 21 Global others market, 2018 - 2030 (USD Million)
FIG. 22 Radiodermatitis market, distribution channel outlook: Key takeaways
FIG. 23 Radiodermatitis market: Distribution channel movement analysis
FIG. 24 Global hospital pharmacies market, 2018 - 2030 (USD Million)
FIG. 25 Global retail pharmacies market, 2018 - 2030 (USD Million)
FIG. 26 Global online pharmacies market, 2018 - 2030 (USD Million)
FIG. 27 Regional market place: Key takeaways
FIG. 28 Regional outlook, 2022 & 2030
FIG. 29 U.S. Radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 30 Canada radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 31 Germany Radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 32 U.K. radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 33 Germany Radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 34 France radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 35 Italy Radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 36 Spain radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 37 Denmark Radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 38 Sweden radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 39 Norway Radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 40 China radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 41 Japan Radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 42 India radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 43 Australia Radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 44 South Korea radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 45 Thailand Radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 46 Brazil radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 47 Mexico Radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 48 Argentina radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 49 South Africa Radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 50 Saudi Arabia radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 51 UAE Radiodermatitis market, 2018 - 2030 (USD Million)
FIG. 52 Kuwait radiodermatitis market, 2018 - 2030 (USD Million)
Companies Mentioned
- Stratpharma AG
- Smith & Nephew
- Molnlycke Health Care Ab
- Derma Sciences Inc.
- Convatec Inc.
- Bmg Pharma S.R.L.
- Acelity
- 3M
- Alliqua Biomedical
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 110 |
| Published | November 2022 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 426.9 Million |
| Forecasted Market Value ( USD | $ 557.1 Million |
| Compound Annual Growth Rate | 3.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
